Happify Health will launch a new investigational prescription-only software called Ensemble as an adjunct therapy for treating major depressive disorder or generalized anxiety disorder, the New York-based company announced on 21 July. The company will conduct clinical studies with a pathway seeking 510(k) clearance from the US Food and Drug Administration.
“The product will be launched as an investigational device where we will be running a real-world evidence study on patients that use it and [we will be] using that data that we collect from the study for the FDA filing [under the software-as-medical devices
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?